Tivozanib
98%
- Product Code: 67642
Alias:
Related CAS number: 475108-18-0
CAS:
682745-41-1
| Molecular Weight: | 509.34 g./mol | Molecular Formula: | C₂₂H₂₂Cl₂N₄O₆ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD34184484 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFRs) to inhibit tumor angiogenesis, thereby slowing the growth and spread of cancer cells. Its application is particularly significant for patients who have previously undergone systemic treatments, offering a targeted therapy option with a favorable safety profile. Tivozanib is administered orally, making it a convenient option for patients requiring long-term management of the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival, making it a valuable addition to the therapeutic arsenal against advanced RCC.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White Powder |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $201.95 |
+
-
|
| 0.025 | 10-20 days | $699.76 |
+
-
|
| 0.100 | 10-20 days | $1,639.04 |
+
-
|
| 0.500 | 10-20 days | $4,097.61 |
+
-
|
Tivozanib
Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It functions as a tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptors (VEGFRs) to inhibit tumor angiogenesis, thereby slowing the growth and spread of cancer cells. Its application is particularly significant for patients who have previously undergone systemic treatments, offering a targeted therapy option with a favorable safety profile. Tivozanib is administered orally, making it a convenient option for patients requiring long-term management of the disease. Clinical trials have demonstrated its efficacy in improving progression-free survival, making it a valuable addition to the therapeutic arsenal against advanced RCC.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :